A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3021 Alone and In Combination With Nivolumab In Patients With Advanced Solid Tumors

Grants and Contracts Details

StatusActive
Effective start/end date11/5/2110/4/23

Funding

  • Labcorp Drug Development Incorporated: $19,931.00